Bypassing fluoroquinolone resistance with quinazolinediones: studies of drug-gyrase-DNA complexes having implications for drug design. - Wikidata - awgldk - TriplyDB

Bypassing fluoroquinolone resistance with quinazolinediones: studies of drug-gyrase-DNA complexes having implications for drug design.

Bypassing fluoroquinolone resistance with quinazolinediones: studies of drug-gyrase-DNA complexes having implications for drug design.

http://www.wikidata.org/entity/Q34756857

about

Exploring the active site of the Streptococcus pneumoniae topoisomerase IV-DNA cleavage complex with novel 7,8-bridged fluoroquinolones Activity of quinolone CP-115,955 against bacterial and human type II topoisomerases is mediated by different interactions.Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases.Crystal structure and stability of gyrase-fluoroquinolone cleaved complexes from Mycobacterium tuberculosis.Suppression of gyrase-mediated resistance by C7 aryl fluoroquinolones.A "Double-Edged" Scaffold: Antitumor Power within the Antibacterial Quinolone.In vitro biological evaluation of novel broad-spectrum isothiazolone inhibitors of bacterial type II topoisomerases.Topoisomerases: Resistance versus Sensitivity, How Far We Can Go?Structure of a quinolone-stabilized cleavage complex of topoisomerase IV from Klebsiella pneumoniae and comparison with a related Streptococcus pneumoniae complex.Are moxifloxacin and levofloxacin equally effective to treat XDR tuberculosis?Structural basis of DNA gyrase inhibition by antibacterial QPT-1, anticancer drug etoposide and moxifloxacin.Suppression of reactive-oxygen-species accumulation accounts for paradoxical bacterial survival at high quinolone concentration.Interactions between Quinolones and Bacillus anthracis Gyrase and the Basis of Drug Resistance.Analytical profiling of mutations in quinolone resistance determining region of gyrA gene among UPEC.Fluoroquinolone-Gyrase-DNA Cleaved Complexes.DNA Topoisomerases as Targets for Antibacterial Agents.Fluoroquinolones as imaging agents for bacterial infection.A new class of antibacterials, the imidazopyrazinones, reveal structural transitions involved in DNA gyrase poisoning and mechanisms of resistance.

P2860

Q28828291-E1FD35BC-E49B-44E9-BDD1-D86282510274 Q35592636-A7E45E28-63E6-4D1C-84BB-7FD49773E9B9 Q35848139-6CBAADC9-CBB5-4A29-A37A-56A926A5C443 Q36607637-94DD7238-7FA0-4723-B10F-976CE8D627F5 Q36817994-E3E67E24-C9E4-4782-BE8C-81B58CD51E11 Q37204002-41C19C99-08E6-4357-AD8B-E42FA0C87DA8 Q38761164-EE1B9A0C-D2F3-4E84-AC5B-FDF3CCF714E8 Q38968355-2CF25BAF-E618-469B-8C12-78BA2DF2313A Q39911518-7AB50B03-6330-47A9-AF70-C01113DC5583 Q40202149-6A69B486-C702-450D-9A39-90E205695347 Q40239631-033E1A4E-71D9-4C65-B036-29D474F52D0A Q46243490-FBC537B0-9D90-42FA-8C46-7442180F670B Q46335874-42F6E236-CD4E-438F-97CC-8B17CBC7086C Q47232788-DC8DE794-7710-4FCD-8428-ED39A99ED293 Q49607576-C8AA17D3-7B22-4C35-89A1-73CF39DCC424 Q49607722-FECE0771-3616-425C-8CBF-1C010CFD9658 Q50048891-AE0C788B-3FFB-4342-A20B-376727327557 Q52355825-D70C1770-B3EB-40DE-B301-7F8D9806D1BA

P2860

Bypassing fluoroquinolone resistance with quinazolinediones: studies of drug-gyrase-DNA complexes having implications for drug design.

http://www.wikidata.org/entity/Q34756857

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

name

Bypassing fluoroquinolone resi ...... implications for drug design.

@ast

Bypassing fluoroquinolone resi ...... implications for drug design.

@en

Bypassing fluoroquinolone resi ...... implications for drug design.

@nl

type

label

Bypassing fluoroquinolone resi ...... implications for drug design.

@ast

Bypassing fluoroquinolone resi ...... implications for drug design.

@en

Bypassing fluoroquinolone resi ...... implications for drug design.

@nl

prefLabel

Bypassing fluoroquinolone resi ...... implications for drug design.

@ast

Bypassing fluoroquinolone resi ...... implications for drug design.

@en

Bypassing fluoroquinolone resi ...... implications for drug design.

@nl

P1433

Q34756857-B9346BFD-4C70-46AF-9A52-5154182B5173

P1476

Q34756857-6445D257-CACA-4D1C-B0FB-B266842E5EC2

P2093

Q34756857-19ECCD6F-FEDD-4FFC-9DFA-A3CEE4ED6550

Q34756857-216E85B0-E3A8-49BF-B809-5FEE0ACCAA93

Q34756857-328C1579-9EF1-4CF5-8D92-95154D379C9D

Q34756857-4A3466A5-625C-4821-A3EF-97043C603919

Q34756857-BE32D992-E778-4F2E-83DE-467A16B7B62C

Q34756857-FE625331-A2EA-492D-AE16-E5FCD4EDF0B6

P2860

Q34756857-04C63EF5-E7A5-46DE-BCC7-FFDFC78B140B

Q34756857-059CB026-21CF-432B-A7A9-C4DBE2F1E90A

Q34756857-0A0C2D53-9DAA-46C4-86E5-F48A1EC22A19

Q34756857-0E859F16-301F-41AF-A238-6B5F68CBE13E

Q34756857-1EBA586E-C287-47B5-BC2E-A63121335E31

Q34756857-238E2683-5D83-414D-A82B-1B3241EBC113

Q34756857-2AC4469A-7CC8-4351-A323-7D2A3CD9E133

Q34756857-36239672-A61C-4F4E-8C72-B5F5ABAE09A2

Q34756857-3EABA949-AEA5-4BDB-82E9-D17688C68983

Q34756857-470B2C83-6329-4566-B98F-82C3E41AD0D2

P304

Q34756857-8D9409BA-1980-4E02-A6E6-883A3EFFDF66

P31

Q34756857-B2FD158C-3BF3-497C-975C-3E3E9ABF2A86

P356

Q34756857-61C977C6-2009-4D23-B4CF-9E4994CECA8F

P433

Q34756857-E000F03B-1A8B-4BFC-8A8B-DD55A677C37F

P478

Q34756857-02497E6E-C9BE-4024-8724-F838BEA4710D

P577

Q34756857-4FFCF0BC-AECF-443A-AADB-54E20960BBD5

P5875

Q34756857-0DF82177-7051-49BF-A414-3107AE1954D8

P698

Q34756857-52E3EE49-C044-4A48-80C0-B7175DE92750

P921

Q34756857-78AA9B0C-38C1-4BCF-8077-6A9D0E189C3F

P932

Q34756857-63842CB0-BB95-444A-9CA0-DB7BC85CA451

P356

P1433

ACS Chemical Biology

P1476

Bypassing fluoroquinolone resi ...... implications for drug design.

@en

P2093

Arkady Mustaev

http://www.w3.org/2001/XMLSchema#string

Gan Luan

http://www.w3.org/2001/XMLSchema#string

James M Berger

http://www.w3.org/2001/XMLSchema#string

Karl Drlica

http://www.w3.org/2001/XMLSchema#string

Robert J Kerns

http://www.w3.org/2001/XMLSchema#string

Tyrell R Towle

http://www.w3.org/2001/XMLSchema#string

P2860

Structural basis of gate-DNA breakage and resealing by type II topoisomerases

Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases

A domain insertion in Escherichia coli GyrB adopts a novel fold that plays a critical role in gyrase function

Type IIA topoisomerase inhibition by a new class of antibacterial agents

Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance

Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide

Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine

Fluoroquinolone-gyrase-DNA complexes: two modes of drug binding.

The use of divalent metal ions by type II topoisomerases.

Use of divalent metal ions in the DNA cleavage reaction of topoisomerase IV.

P304

2895-2904

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/CB500629K

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2014-11-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

266951047

http://www.w3.org/2001/XMLSchema#string

P698

25310082

http://www.w3.org/2001/XMLSchema#string

P921

P932

4273985

http://www.w3.org/2001/XMLSchema#string